Cardiology AdvisorHigh Prevalence of Premature ASCVD Found in Arab American Patients

ℹ️ Observational Association Only Evidence

A retrospective registry analysis examined ASCVD and cardiometabolic conditions among 49,440 adults identified as Arab American through a name-based algorithm. Traditional risk factors clustered among patients with ASCVD, including those meeting the study’s premature-disease definition. The findings characterize a population that may be incompletely captured in routine demographic data. However, one health system’s prevalence estimates cannot establish national burden, excess risk relative to other populations, or ancestry-specific treatment thresholds.

Clinical Considerations

• ASCVD affected 15.2% of the cohort; 3.4% met the premature definition, based on age at last encounter rather than diagnosis.
• Premature ASCVD used different age cutoffs: younger than 65 years for women and younger than 55 years for men.
• Overall ASCVD prevalence was 20.5% in men versus 10.5% in women; premature ASCVD prevalence was 3.4% in both.
• Hyperlipidemia and hypertension had the strongest adjusted associations with premature ASCVD, with odds ratios of 4.18 and 3.88, respectively.
• The name-based algorithm had high specificity but moderate sensitivity; missed identification and uncertain transferability may affect the cohort’s composition.
• Single-system EHR data and no reported external population comparator limit generalizability; prevalence odds ratios are not prospective risk estimates.

Practice Applications

• Review individual lipid, blood pressure, diabetes, and smoking histories without treating ancestry as a substitute for clinical risk assessment.
• Interpret premature-disease estimates cautiously: encounter-based age can miss patients whose disease began earlier but who subsequently exceeded the cutoff.
• Avoid inferring that older age protects against premature ASCVD or that these findings establish ancestry-specific screening or treatment recommendations.